Pancreatic Cancer Research

Clinical trialPhase 2Terminated

Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

A Phase II, Randomized, Double-blind, Trial Comparing Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

Outcome
Stopped early. Results posted; no analysis attachedSlow accrual (Enrollment)
Phase
Phase 2
Status
Terminated
Study type
Interventional
Start
5 August 2022
Ended
27 August 2023
Enrollment
4 participants
Sites
1
Primary outcomes
Change in the Rate of Depression
Sponsor type
Academic / other
Results posted
10 December 2025
Last update
10 December 2025

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; no analysis attachedAs posted on ClinicalTrials.gov ↗, registry record of 10 December 2025
Primary outcome
Change in the Rate of DepressionParticipants Receiving Escitalopram: 13, n = 1Values: QIDS scoreTime frame: 12 weeks from the start of treatmentNo analysis posted for this outcome (outcome 1)
Participants
Participants Receiving Escitalopram: 2 started, 1 completedParticipants Receiving Placebo: 2 started, 0 completed
Serious adverse events
Participants Receiving Escitalopram: 1 of 2Participants Receiving Placebo: 1 of 2Participants with at least one serious adverse event, of those at risk, as posted
1 secondary outcome
Quality of Life Using FACT-Hep (The Functional Assesment of Cancer Therapy-Hepatobiliary)…
Participants Receiving Escitalopram 90, n=1 [FACTS score]

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

Use of antidepressants for participants with localized pancreatic and periampullary cancer receiving neoadjuvant therapy.

Detailed description public domain (ClinicalTrials.gov)

Anti-depressants have been shown to be beneficial in cancer participants. They reduce depressive symptoms and improve quality of life. Randomized trials have shown that antidepressants can reduce the development of depression in non-depressed participants with breast, melanoma, and head and neck cancers. It has been shown that treating depression can impact survival in cancer participants. Additionally, depressed pancreatic cancer participants have worse survival. Therefore, anti-depressants may also have implications for cancer treatment.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Change in the Rate of Depression [12 weeks from the start of treatment]. Number, QIDS score. Participants Receiving Escitalopram (n=1): 13.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Quality of Life Using FACT-Hep (The Functional Assesment of Cancer Therapy-Hepatobiliary) Survey [Up to 12 weeks from the treatment date]. Number, FACTS score. Participants Receiving Escitalopram (n=1): 90.